Literature DB >> 2337907

Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

W H De Jong1, E C De Boer, A P Van der Meijden, P Vegt, P A Steerenberg, F M Debruyne, E J Ruitenberg.   

Abstract

Urine samples were obtained from patients with superficial bladder cancer after immunotherapy with bacillus Calmette-Guérin (BCG). The patients were repeatedly (once a week for 6 consecutive weeks) treated with intravesical administration of approximately 5 X 10(8) culturable particles of BCG. Some patients received more than six BCG instillations. The urine samples were investigated for the presence of interleukin-2 (IL-2) in an in vitro bioassay using a murine cytotoxic T cell line (CTTL-16) that shows IL-2-dependent growth. Preliminary experiments indicated the presence of inhibitory factors in the urine. This inhibitory activity was abolished after 24 h dialysis. In a neutralization assay with both polyvalent and monoclonal anti-(human IL-2) antibody it was demonstrated that there was indeed IL-2 in the urine samples. In 8 of 11 patients the presence of IL-2 in the urine was demonstrated. The IL-2 production was directly related to the BCG administration as samples obtained just before the BCG instillation were always negative. In IL-2-positive samples a maximum level of IL-2 was observed between 2 h and 6 h after the BCG instillation. In urine samples obtained 24 h after the BCG IL-2 was not detected. In most patients the urine became positive after the third or fourth PCG instillation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337907     DOI: 10.1007/bf01744734

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Histopathology of BCG and thiotepa treated bladders.

Authors:  P Guinan; M Shaw; V Ray
Journal:  Urol Res       Date:  1986

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.

Authors:  D R Kelley; T L Ratliff; W J Catalona; A Shapiro; J M Lage; W C Bauer; E O Haaff; S M Dresner
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

4.  Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.

Authors:  J M Lage; W C Bauer; D R Kelley; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-05       Impact factor: 7.450

5.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989

7.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

8.  Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.

Authors:  T L Ratliff; E O Haaff; W J Catalona
Journal:  Clin Immunol Immunopathol       Date:  1986-08

9.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

Review 10.  Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma.

Authors:  W H de Jong; J S Teppema; S S Wagenaar; M Paques; P A Steerenberg; E J Ruitenberg
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1986
View more
  13 in total

Review 1.  Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Authors:  Akhil Muthigi; Arvin K George; Sam J Brancato; Piyush K Agarwal
Journal:  Ther Adv Urol       Date:  2016-02-09

Review 2.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

Review 3.  Toll-like receptor agonists in cancer therapy.

Authors:  Sylvia Adams
Journal:  Immunotherapy       Date:  2009-11       Impact factor: 4.196

4.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

5.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 6.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

7.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

8.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

Authors:  E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

10.  Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.

Authors:  A M Jackson; A B Alexandrov; S Prescott; K James
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.